Viloxazine
Viloxazine. Selective NET inhibition + 5-HT2C agonism + 5-HT2B antagonism. Non-stimulant ADHD treatment approved 2021 (originally marketed in… Oral half-life 7 h.
Selective NET inhibition + 5-HT2C agonism + 5-HT2B antagonism. Non-stimulant ADHD treatment approved 2021 (originally marketed in Europe as antidepressant 1970s-2002). No abuse potential.
PK: BOTH CITED PAPERS ARE RATIO-ONLY AND THE ABSORPTION RATE CAME FROM A Tmax THAT DOES NOT EXIST. This record was the entry point to a wider finding: an authoring script derived absorption rates for forty-four drugs from assumed peak times, claiming each was verbatim from a primary study, and THIS ONE CITES AN ABSTRACT CONTAINING NO PEAK TIME AT ALL — only co-administration ratio percentages. The rate is removed rather than repaired. THE STORED HALF-LIFE IS ESSENTIALLY RIGHT AND ONLY NEEDED A SOURCE: a hepatic-impairment study gives matched healthy controls verbatim at 6.7, 6.0 and 7.1 hours. MY FORMULATION PRIOR WAS REFUTED AND THE RECORD IS CORRECT: viloxazine ships only as an extended-release capsule, both cited studies use it, and the immediate-release literature gives 2.2 to 4.3 hours, so the stored seven hours is genuinely formulation-extended and there is no flip-flop. THE Cmax-OVER-AUC IDENTITY NEVERTHELESS FAILS, and instructively: three independent control cohorts give an exposure-to-peak ratio of 23.7, 24.2 and 22.1 hours — strikingly dose-independent — against the 16.6 h this record parameters produce, and reaching it would need a half-life contradicting those same verbatim controls. The signature is extended-release absorption continuing past the peak, which one first-order rate cannot describe. The record preserves the PEAK and under-predicts exposure by about 29%.
Pharmacokinetics
- Oral — t½ 7 h · F 88% · Vd 98 L
Sources: PMID:34652564, PMID:33368026, PMID:42503060